47
https://pubmed.ncbi.nlm.nih.gov/38116445
Researchers at Novartis have developed a chiral synthesis route for muscarinic M4 agonists using biocatalytic synthesis of spirocyclic diamine building blocks, leading to the identification of selective M1/M4 agonists.